Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM

Seeking Alpha03:01

UBS Maintains Intra-Cellular Therapies(ITCI.US) With Hold Rating, Raises Target Price to $87

Futu NewsNov 20 02:31 · Ratings

Express News | Intra-Cellular Therapies Inc : UBS Raises Target Price to $87 From $79

BreakingsNov 19 23:39

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

GlobeNewswireNov 19 21:00

US Manufacturing Index Rises To 43, Highest Since 2020

Business TodayNov 16 15:13

Intra-Cellular Therapies Insider Sold Shares Worth $3,692,100, According to a Recent SEC Filing

MT NewswiresNov 15 16:51